New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

NCT07559760 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab

Sponsor

The First Hospital of Jilin University